From bench to bedside: novel mechanisms and therapeutic advances through the development of selective peroxisome proliferator-activated receptor γ modulators

Risk of Fractures with Glitazones

(2009) Michael Bodmer et al.   DRUG SAFETY

Fibroblast Growth Factor 21 Controls Glycemia via Regulation of Hepatic Glucose Flux and Insulin Sensitivity

(2009) Eric D. Berglund et al.   ENDOCRINOLOGY

Relationship between peroxisome proliferator-activated receptor-γ activation and the ameliorative effects of ascochlorin derivatives on type II diabetes

(2009) Junji Magae et al.   JOURNAL OF ANTIBIOTICS

INT131: A Selective Modulator of PPARγ

(2009) Alykhan Motani et al.   JOURNAL OF MOLECULAR BIOLOGY

PPAR-α and PPAR-γ agonists for type 2 diabetes

(2009) Bernard Charbonnel   LANCET

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

(2009) Robert R Henry et al.   LANCET

MBX-102/JNJ39659100, a Novel Peroxisome Proliferator-Activated Receptor-Ligand with Weak Transactivation Activity Retains Antidiabetic Properties in the Absence of Weight Gain and Edema

(2009) Francine M. Gregoire et al.   MOLECULAR ENDOCRINOLOGY

Peroxisome Proliferator-Activated Receptor Gamma Agonists in Kidney Disease – Future Promise, Present Fears

(2009) Zhiguo Mao et al.   NEPHRON CLINICAL PRACTICE

MBX-102/JNJ39659100, a Novel Non-TZD Selective Partial PPAR- Agonist Lowers Triglyceride Independently of PPAR- Activation

(2009) Apurva Chandalia et al.   PPAR Research

The Development of INT131 as a Selective PPAR Modulator: Approach to a Safer Insulin Sensitizer

(2008) Linda S. Higgins et al.   PPAR Research